Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) has announced its financial and operational results for the second quarter of 2026, highlighting a significant reduction in expenses and a major regulatory milestone for its lead drug candidate. The company reported a 53% year-over-year decrease in operating expenses, which totaled $2.29 million, and a 47% drop in general and administrative expenses to $1.76 million. This cost discipline has strengthened its balance sheet, with combined cash, cash equivalents, and digital assets reaching approximately $9.5 million as of June 30, up from $4.1 million at the end of 2025. Management noted that the current liquidity is sufficient to fund planned operations to at least October 2027, assuming the first-half 2026 cash burn rate.
The most significant development came after the quarter-end when the U.S. Food and Drug Administration (FDA) approved Quantum’s Investigational New Drug (IND) application for Lucid-MS. This approval allows the company to proceed with a randomized, double-blind, placebo-controlled Phase 2 clinical trial in patients with progressive multiple sclerosis (MS). Lucid-MS is a patented new chemical entity that has shown in preclinical models the ability to prevent and reverse myelin degradation, the underlying mechanism of MS. This advancement represents a potential breakthrough in treating a condition for which there are limited therapeutic options.
“The FDA’s approval of our IND application is a pivotal step for Quantum BioPharma and for patients living with progressive MS,” said a company spokesperson. “We are committed to advancing Lucid-MS through clinical development, and our reduced expense base positions us well to execute on our strategic priorities.”
In addition to its MS program, Quantum BioPharma is dedicated to building a portfolio of innovative assets for challenging neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. The company retains a 19.84% ownership stake in Unbuzzd Wellness Inc., the company that markets the over-the-counter version of its UNBUZZD product. The agreement includes royalty payments of 7% of sales until payments total $250 million, after which the royalty drops to 3% in perpetuity. Quantum retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses.
The financial improvements and regulatory progress could have significant implications for the biotech industry and for patients suffering from progressive MS. Currently, there are few effective treatments for this form of the disease, and a successful Phase 2 trial could pave the way for a new therapeutic option. For investors, the company’s extended cash runway reduces near-term dilution risk, while the Phase 2 catalyst offers potential upside.
For more information about Quantum BioPharma, visit the company’s newsroom at https://nnw.fm/QNTM. The full press release can be viewed at https://nnw.fm/dlAAe.
